Atherosclerosis
Volume 196, Issue 2 , Pages 505-513, February 2008

CETP activity variation in mice does not affect two major HDL antiatherogenic properties: Macrophage-specific reverse cholesterol transport and LDL antioxidant protection

  • Noemí Rotllan

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • ,
  • Laura Calpe-Berdiel

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • ,
  • Amy Guillaumet-Adkins

      Affiliations

    • Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
  • ,
  • Songül Süren-Castillo

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • ,
  • Francisco Blanco-Vaca

      Affiliations

    • Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Corresponding Author InformationCorresponding authors at: Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Antoni M Claret 167, 08025 Barcelona, Spain. Tel.: +34 93 2919451; fax: +34 93 2919196.
  • ,
  • Joan Carles Escolà-Gil

      Affiliations

    • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • Corresponding Author InformationCorresponding authors at: Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Antoni M Claret 167, 08025 Barcelona, Spain. Tel.: +34 93 2919451; fax: +34 93 2919196.

Received 16 February 2007; received in revised form 9 May 2007; accepted 10 May 2007. published online 25 June 2007.

Abstract 

CETP inhibition increases HDL cholesterol levels and presumably could contribute to human atheroprotection via increasing macrophage-specific reverse cholesterol transport (RCT) and antioxidant properties of HDL. However, the impact of CETP activity variation on these two antiatherogenic functions of HDL remain unknown. In this study, we assessed the effects of overexpressing CETP in transgenic (Tg) mice on macrophage-specific RCT and HDL ability to protect against LDL oxidative modification. [3H]cholesterol-labeled macrophages were injected intraperitoneally into mice maintained on a chow diet or an atherogenic diet, after which the appearance of [3H]cholesterol in plasma, liver and feces over 48h was determined. The degree of protection of oxidative modification of LDL coincubated with HDL was evaluated by measuring relative electrophoretic mobility and dichlorofluorescein fluorescence. CETP-Tg mice presented decreased radiolabeled HDL-bound [3H]cholesterol 24 and 48h after the label injection. However, the magnitude of macrophage-derived [3H]cholesterol in liver and feces did not differ between CETP-Tg and control mice on either diet. Similar results were found when [3H]cholesterol-labeled endogenous peritoneal macrophages were injected into the CETP-Tg and control mice. Further, the injection of endogenous macrophages from CETP-Tg mice did not alter macrophage RCT in control mice. HDL from CETP-Tg and control mice protected LDL from oxidative modification similarly, and paraoxonase 1, platelet activated factor acetyl-hydrolase and lecithin-cholesterol acyl transferase activities of transgenic mice did not differ from those of control mice. In conclusion, CETP overexpression in transgenic mice does not affect RCT from macrophages to feces in vivo or the protection conferred by HDL against LDL oxidative modification.

Keywords: CETP, HDL, Macrophages, Paraoxonase, Reverse cholesterol transport

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(07)00339-5

doi:10.1016/j.atherosclerosis.2007.05.007

Atherosclerosis
Volume 196, Issue 2 , Pages 505-513, February 2008